Samlyn Capital’s Legend Biotech LEGN Stock Holding History

Samlyn Capital’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-500	Closed	-$25K	–	108
2022 Q4	$25K	Buy	+500	New	+$24.2K	﹤0.01%	88

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Samlyn Capital's LEGN Position: Q4 2023 in Review

Samlyn Capital sold out of Legend Biotech (LEGN) in Q4 2023, closing a stake of 407,546 shares — an estimated $27.4M sold.

Samlyn Capital first reported a position in LEGN in Q2 2020 and held it in 7 quarters. The position peaked at $36.4M in Q3 2022. 206 funds tracked by Wall St. Rank hold LEGN as of Q4 2023.

Samlyn Capital reported no remaining Legend Biotech position as of Q4 2023 after selling out during the quarter.
Samlyn Capital sold 407,546 Legend Biotech shares in Q4 2023, an estimated $27.4M.
Samlyn Capital first reported a position in Legend Biotech in Q2 2020 and held it in 7 quarters.
Samlyn Capital's Legend Biotech position peaked at $36.4M in Q3 2022.
206 funds tracked by Wall St. Rank held Legend Biotech as of Q4 2023.

Based on Samlyn Capital's 13F filing for Q4 2023, filed 14 Feb 2024.